Skip to main content

Research Repository

Advanced Search

PreclinHUPET2: Enabling Enhanced Preclinical Nuclear Imaging For The North Of England

People Involved

Profile image of Dr Louis Allott

Dr Louis Allott Louis.Allott@hull.ac.uk
Lecturer in Translational Radiopharmaceutics

Profile image of Dr Azeem Saleem

Dr Azeem Saleem A.Saleem@hull.ac.uk
Reader and Honorary Consultant in Clinical Oncology

Profile image of Professor Michael Lind

Professor Michael Lind M.J.Lind@hull.ac.uk
Foundation Professor of Oncology/ Head of the Joint Centre for Cancer Studies

Profile image of Professor Carl Redshaw

Professor Carl Redshaw C.Redshaw@hull.ac.uk
Professor of Inorganic Materials Chemistry and REF Lead for Chemistry

Project Description

The grant application is to upgrade the preclinical scanning facilities for nuclear imaging of small animals (mice and rats) at the University of Hull. These facilities are used for research into disease and human health. The main areas that will be tackled are the diagnosis and staging of disease (particularly cancer) along with the personalised selection of treatment (e.g. whether radiotherapy or chemotherapy is the best treatment, and even which drug will be the most likely to successfully treat the patient). Preclinical scanning allows the use of the animal models in the most effective and essential way to validate radiopharmaceutical drugs before they can be taken into clinical trials in humans. The quality of the data also means that fewer animals are required to understand the drug and demonstrate whether it is suitable for clinical trials in humans.

Radiopharmaceuticals use a miniscule amount of a radioactive substance, generally produced on a small particle accelerator, to allow us to locate disease, track biological processes and select treatment in patients. They provide the most sensitive method and only effective way for tracking molecular level processes non-invasively in the human body.

We have invented new radiopharmaceutical drug candidates at the University of Hull and are also working with both UK based and international pharmaceutical companies to provide data to allow their drugs to progress through to clinical testing and ultimately approved for routine human use (i.e. in the NHS). We support clinicians in developing and testing new drug treatments to determine effective doses and treatment regimes for them to use in patients. The high-quality information obtained from the preclinical imaging studies means that these compounds can rapidly and efficiently be tested and validated. This forms part of a translational pathway in Hull with preclinical research linking through to NHS patient scanning. We can carry out research patient scans and will use the preclinical scanners to gather the data to take new radiopharmaceuticals through to the clinic using our new human production facility on the hospital site (the Molecular Imaging Research Centre at Castle Hill Hospital, Hull University Teaching Hospitals NHS Trust).

Project Acronym PreclinHUPET
Status Project Complete
Funder(s) Medical Research Council
Value £657,700.00
Project Dates Feb 1, 2023 - Jan 31, 2024
Partner Organisations 00 No Partners


You might also like

The role of bacteria in the skin: Cold atmospheric plasma for the treatment of pathological skin healing Apr 1, 2017 - Mar 31, 2020
Chronic wounds remain a major area of unmet clinical need, with infection a principle contributing factor to wound chronicity. This project builds upon strong preliminary data suggesting that healing outcome can be directly linked to both wound micro... Read More about The role of bacteria in the skin: Cold atmospheric plasma for the treatment of pathological skin healing.